Compare GameStop Corp. (GME) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Merck & Co., Inc. — how do they compare? GameStop Corp. trades at $21.95 (market cap $9.99B), while Merck & Co., Inc. trades at $127.97 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 30.6× GameStop Corp.'s market cap, and Merck & Co., Inc. pays a 2.75% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | MRK | |
|---|---|---|
Market Cap | $9.99B | $305.29B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $129.52 |
52-Week Low | $19.94 | $77.60 |
Enterprise Value | $5.96B | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.36, down 0.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue declined to $3.82 billion in 2025, but net income improved to $131.3 million, reflecting a profit margin of 3.43%. Recent developments include a partnership with Uber Eats and ongoing efforts to acquire eBay, as announced in Business Wire on June 26, 2026.
The outlook is mixed, with positive EBITDA guidance above $600 million for fiscal 2026 offering upside potential, but risks include revenue declines and dependence on physical media amid Sony's shift away from discs. Analyst sentiment is cautious, with only 16.67% buy ratings, suggesting limited near-term conviction despite operational improvements.
MRK trades at $127.65, up 5.67% today, reflecting strong momentum. The stock shows a bullish technical signal with moving averages supporting the uptrend. Fundamentally, the company reported robust 2025 results with revenue of $65.01B and net income of $18.25B, and recently announced the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline. Analyst consensus is strongly positive with a $137.30 price target.
The outlook for MRK is favorable, driven by earnings beats, strategic acquisitions, and solid profitability. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. The stock presents a growth opportunity with upside to the consensus target, though investors should monitor integration of new acquisitions and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
